Part A (Blinded): mRNA-1273 vs Part A (Blinded): Placebo: Part A: Number of Participants With a Secondary Case Definition of COVID-19 Starting 14 Days After Second Dose
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.00406 | 0.00314 | 0.00524 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.057 | 0.0533 | 0.0609 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | -0.0529 | -0.057 | -0.049 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 0.0713 | 0.0546 | 0.0929 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 0.0675 | 0.0516 | 0.0882 | log | ClinicalTrials.gov | |
| Number needed to treat, for one fewer participant with the outcome on Part A (Blinded): mRNA-1273 than on Part A (Blinded): Placebo | 18.9 | 17.6 | 20.4 | from the risk difference interval | ClinicalTrials.gov |
Groups 2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | Part A (Blinded): mRNA-1273 | Participants received 100 μg mRNA-1273 on a 2-dose injection schedule (Day 1 and Day 29). | 58 | 14,287 | OG001 | ClinicalTrials.gov |
| Group 2 | Part A (Blinded): Placebo | Participants received mRNA-1273-matching placebo on a 2-dose injection schedule (Day 1 and Day 29). | 807 | 14,164 | OG000 | ClinicalTrials.gov |
Outcome 5
| Field | Value | Source |
|---|---|---|
| Type | SECONDARY | ClinicalTrials.gov |
| Title | Part A: Number of Participants With a Secondary Case Definition of COVID-19 Starting 14 Days After Second Dose | ClinicalTrials.gov |
| Description | Secondary case definition of COVID-19 was defined as the presence of at least 1 of the following systemic symptoms: fever (temperature~≥38ºC), or chills, cough, shortness of breath or difficulty breathing, fatigue, muscle aches or body aches, headache, new loss of taste or smell, sore throat, nasal congestion or rhinorrhea, nausea or vomiting, or diarrhea and a positive nasopharyngeal swab, nasal swab, or saliva sample (or respiratory sample, if hospitalized) for SARS-CoV-2 by RT-PCR. | ClinicalTrials.gov |
| Time frame | From Day 43 (14 days after second dose) up to approximately 7 months after the second dose | ClinicalTrials.gov |
| Population | Part A PP Set. Number analyzed=participants evaluable at specified timepoint. | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19 | ClinicalTrials.gov |
| NCT number | NCT04470427 | ClinicalTrials.gov |
| Phases | PHASE3 | ClinicalTrials.gov |
| Conditions | SARS-CoV-2 | ClinicalTrials.gov |
| Interventions | mRNA-1273, Placebo | ClinicalTrials.gov |
| Lead sponsor | ModernaTX, Inc. | ClinicalTrials.gov |
| Results first posted | 2024-03-21 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT04470427?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.